$131.43
0.07% today
NYSE, Oct 22, 10:00 pm CET
ISIN
US66987V1098
Symbol
NVS

Novartis ADR Stock price

$131.34
+7.98 6.47% 1M
+20.80 18.82% 6M
+34.03 34.97% YTD
+15.61 13.49% 1Y
+58.35 79.95% 3Y
+51.69 64.89% 5Y
+44.63 51.48% 10Y
+81.61 164.11% 20Y
NYSE, Closing price Tue, Oct 21 2025
-0.45 0.34%
ISIN
US66987V1098
Symbol
NVS
Industry

Key metrics

Basic
Market capitalization
$249.0b
Enterprise Value
$274.6b
Net debt
$25.6b
Cash
$6.7b
Shares outstanding
1.9b
Valuation (TTM | estimate)
P/E
18.9 | 14.5
P/S
4.5 | 4.4
EV/Sales
5.0 | 4.9
EV/FCF
16.3
P/B
5.9
Dividends
DPS
$3.99
Yield 1Y | 5Y
3.0% | 3.6%
Growth 1Y | 5Y
6.8% | 6.4%
Payout 1Y | 3Y
63.7% | 63.3%
Increased
6 Years
Financials (TTM | estimate)
Revenue
$54.8b | $56.4b
EBITDA
$18.6b | $23.4b
EBIT
$18.3b | $21.0b
Net Income
$13.7b | $17.6b
Free Cash Flow
$16.8b
Growth (TTM | estimate)
Revenue
12.2% | 9.1%
EBITDA
45.4% | 41.5%
EBIT
44.8% | 28.5%
Net Income
-15.6% | 47.1%
Free Cash Flow
41.3%
Margin (TTM | estimate)
Gross
76.1%
EBITDA
33.9% | 41.5%
EBIT
33.5%
Net
24.9% | 31.1%
Free Cash Flow
30.6%
Financial Health
Equity Ratio
43.1%
Return on Equity
27.1%
ROCE
25.2%
ROIC
21.6%
Debt/Equity
0.8
More
EPS
$7.0
FCF per Share
$8.7
Short interest
0.2%
Employees
76k
Rev per Employee
$680.0k
Show more

Is Novartis ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Novartis ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a Novartis ADR forecast:

13x Buy
41%
15x Hold
47%
4x Sell
13%

Analyst Opinions

32 Analysts have issued a Novartis ADR forecast:

Buy
41%
Hold
47%
Sell
13%

Financial data from Novartis ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
54,842 54,842
12% 12%
100%
- Direct Costs 13,098 13,098
6% 6%
24%
41,744 41,744
14% 14%
76%
- Selling and Administrative Expenses 13,132 13,132
5% 5%
24%
- Research and Development Expense 9,678 9,678
9% 9%
18%
18,608 18,608
45% 45%
34%
- Depreciation and Amortization 262 262
115% 115%
0%
EBIT (Operating Income) EBIT 18,346 18,346
45% 45%
33%
Net Profit 13,654 13,654
16% 16%
25%

In millions USD.

Don't miss a Thing! We will send you all news about Novartis ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novartis ADR Stock News

Neutral
GlobeNewsWire
about 16 hours ago
Basel, October 22, 2025 – Novartis today announced that Cosentyx® (secukinumab) met the primary endpoint and all secondary endpoints in the Phase III REPLENISH trial1. Cosentyx demonstrated statistically significant and clinically meaningful sustained remission vs placebo at Week 52 in adults with polymyalgia rheumatica (PMR)1. Data will be presented at an upcoming medical congress and submitte...
Positive
Reuters
3 days ago
Swiss drugmaker Novartis said on Sunday its targeted radiotherapy treatment Pluvicto reduced the risk of progression or death in patients with prostate cancer by 28%.
Neutral
GlobeNewsWire
3 days ago
Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition trial in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2025. Pluvicto plus standard of care (SoC) (androgen receptor pathway inhibitor [ARPI] + androgen deprivation therapy [ADT]) demonstrated a statistically signifi...
More Novartis ADR News

Company Profile

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Vasant Narasimhan
Employees 75,883
Founded 1996
Website www.novartis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today